直接口服抗凝药在非瓣膜性房颤中的有效性与安全性:多数据库队列研究及荟萃分析
该研究通过9个行政医疗数据库开展多中心匹配队列研究,比较达比加群、利伐沙班和阿哌沙班在非瓣膜性房颤患者中的有效性与安全性,并采用随机效应荟萃分析合并估计值。主要终点为缺血性卒中或系统性血栓栓塞的合并风险比。结果显示阿哌沙班较利伐沙班降低卒中及出血风险,与达比加群风险相似。
要点
- 利伐沙班较达比加群大出血风险升高(pHR 1.26,95%CI 1.09–1.46)。
- 阿哌沙班较利伐沙班卒中/栓塞风险降低(pHR 0.85,95%CI 0.74–0.99)。
- 阿哌沙班较利伐沙班大出血风险降低(pHR 0.61,95%CI 0.53–0.70)。
核心结论
- 阿哌沙班与利伐沙班相比,卒中及出血风险更低,与达比加群风险相似。
研究设计与样本
- 多中心匹配队列研究,辅以二次荟萃分析,覆盖9个行政医疗数据库。
- 纳入新启动达比加群、利伐沙班或阿哌沙班抗凝的成人非瓣膜性房颤患者。
- 构建3个配对队列进行直接口服抗凝药两两比较,采用Cox比例风险回归及随机效应荟萃分析合并估计。
主要发现
- 利伐沙班 vs 达比加群:缺血性卒中或系统性血栓栓塞 pHR 1.11(95%CI 0.93–1.32),大出血 pHR 1.26(95%CI 1.09–1.46),复合终点 pHR 1.17(95%CI 1.05–1.30)。
- 阿哌沙班 vs 达比加群:缺血性卒中或系统性血栓栓塞 pHR 0.91(95%CI 0.74–1.12),大出血 pHR 0.89(95%CI 0.75–1.05),复合终点 pHR 0.94(95%CI 0.78–1.14)。
- 阿哌沙班 vs 利伐沙班:缺血性卒中或系统性血栓栓塞 pHR 0.85(95%CI 0.74–0.99),大出血 pHR 0.61(95%CI 0.53–0.70),复合终点 pHR 0.82(95%CI 0.76–0.88)。
临床怎么用
- 在非瓣膜性房颤抗凝选择中,可参考阿哌沙班较利伐沙班更低的卒中及出血风险数据。
- 阿哌沙班与达比加群在卒中和出血风险上表现相似,选择时需结合患者个体情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: There are conflicting signals in the literature about comparative safety and effectiveness of direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (NVAF). METHODS: We conducted multicentre matched cohort studies with secondary meta-analysis to assess safety and effectiveness of dabigatran, rivaroxaban and apixaban across 9 administrative healthcare databases. We included adults with NVAF initiating anticoagulation therapy (dabigatran, rivaroxaban or apixaban), and constructed 3 cohorts to compare DOACs pairwise. The primary outcome was pooled hazard ratio (pHR) of ischaemic stroke or systemic thromboembolism. Secondary outcomes included pHR of major bleeding, and a composite of stroke, major bleeding, or all-cause mortality. We used proportional hazard Cox regressions models, and pooled estimates were obtained with random effect meta-analyses. RESULTS: The cohorts included 73 414 new users of dabigatran, 92 881 of rivaroxaban, and 61 284 of apixaban. After matching, the pHRs (95% confidence intervals) comparing rivaroxaban initiation to dabigatran were: 1.11 (0.93, 1.32) for ischaemic stroke or systemic thromboembolism, 1.26 (1.09, 1.46) for major bleeding, and 1.17 (1.05, 1.30) for the composite endpoint. For apixaban vs dabigatran, they were: 0.91 (0.74, 1.12) for ischaemic stroke or systemic thromboembolism, 0.89 (0.75, 1.05) for major bleeding, and 0.94 (0.78 to 1.14) for the composite endpoint. For apixaban vs rivaroxaban, they were: 0.85 (0.74, 0.99) for ischaemic stroke or systemic thromboembolism, 0.61 (0.53, 0.70) for major bleeding, and 0.82 (0.76, 0.88) for the composite endpoint. CONCLUSION: We found that apixaban use is associated with lower risks of stroke and bleeding compared with rivaroxaban, and similar risks compared with dabigatran.
引用
- Durand M, Schnitzer ME, Pang M, et al. Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multi-database cohort study with meta-analysis. Br J Clin Pharmacol. 2020. PMID: 33242339. doi:10.1111/bcp.14669
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。